

CONTENTS

| | |
|---|-----|
| Preface | v |
| Contributors | ix |
| Introduction | xi |
| 1 Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: <i>Preclinical and Clinical Modulation</i> | 1 |
| G. J. Peters | |
| 2 Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: <i>Past and Future Directions</i> | 29 |
| Gérard Milano | |
| 3 Biochemical Bases of the 5-Fluorouracil–Folinic Acid Interaction and of its Limitations: <i>A Retrospective Analysis</i> | 37 |
| Richard G. Moran | |
| 4 Molecular Mechanisms Regulating the Expression of Thymidylate Synthase | 67 |
| John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, and Edward Chu | |
| 5 Regulation of Thymidylate Synthase Gene Expression and Drug Response: <i>Posttranscriptional Regulation and Cell Population Density</i> | 83 |
| Bruce J. Dolnick | |
| 6 Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action | 93 |
| Janet A. Houghton | |
| 7 Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications | 107 |
| Francis Lévi | |
| 8 Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents | 129 |
| Alberto F. Sobrero and Ornella Belvedere | |
| 9 Noninvasive Studies of Fluoropyrimidines | 139 |
| Walter Wolf, Cary A. Presant, and Victor Waluch | |
| 10 Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: <i>Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors</i> | 153 |
| Shousong Cao, Gunnar Hapke, and Youcef M. Rustum | |

| | | |
|----|---|-----|
| 11 | Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer | 163 |
| | <i>Aimery de Gramont and Christophe Louvet</i> | |
| 12 | Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases | 175 |
| | <i>Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti, and M. Adelaide Pessi</i> | |
| 13 | Fluoropyrimidines in Advanced Colorectal Cancer: <i>A Review of Six Consecutive Meta-Analyses</i> | 183 |
| | <i>Pascal Piedbois and Marc E. Buyse</i> | |
| 14 | The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer | 191 |
| | <i>Charles Erlichman, Richard M. Goldberg, and Daniel J. Sargent</i> | |
| 15 | Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: <i>The NSABP Experience</i> | 199 |
| | <i>Roy E. Smith, Eleftherios P. Mamounas, and Norman Wolmark</i> | |
| 16 | Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies | 209 |
| | <i>Paulo M. Hoff and Everardo D. Saad</i> | |
| 17 | The Development of Oral UFT with and without Leucovorin | 219 |
| | <i>Geert H. Blijham</i> | |
| 18 | UFT in Elderly Patients with Colorectal Cancer | 229 |
| | <i>Albert Abad, and José Luis Manzano</i> | |
| 19 | Clinical Trials of the Eniluracil/5-Fluorouracil Combination | 235 |
| | <i>Hedy L. Kindler and Richard L. Schilsky</i> | |
| 20 | Discovery and Preclinical Pharmacology of Capecitabine | 249 |
| | <i>Hideo Ishitsuka</i> | |
| 21 | Capecitabine, A Tumor-Targeting Oral Fluoropyrimidine: <i>Molecular Rationale and Clinical Validation</i> | 261 |
| | <i>Dvorit Samid</i> | |
| 22 | Capecitabine: <i>A Rationally Developed Anticancer Drug</i> | 275 |
| | <i>Daniel R. Budman</i> | |
| 23 | Preclinical and Clinical Practice of S-1 in Japan | 285 |
| | <i>Tetsuhiko Shirasaka and Tetsuo Taguchi</i> | |
| 24 | Preclinical and Clinical Practice of Low-Dose FP Therapy in Japan: <i>Japanese Use of Low-Dose FP Therapy</i> | 303 |
| | <i>Tetsuhiko Shirasaka, Akihito Tsuji, Susumu Yamamitsu, and Tetsuo Taguchi</i> | |
| | Index | 319 |



<http://www.springer.com/978-0-89603-956-8>

Fluoropyrimidines in Cancer Therapy

Rustum, Y.M. (Ed.)

2003, XII, 326 p., Hardcover

ISBN: 978-0-89603-956-8

A product of Humana Press